Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop...

Related Keywords

United States ,Netherlands ,Sydney ,New South Wales ,Australia ,American ,Holland ,Guggerm Bombesin ,Andrei Iagaru ,Alan Taylor ,Prnewswire Clarity Pharmaceuticals ,American Cancer Institute ,American Cancer Society ,Clarity Pharmaceuticals ,Biochemical Recurrence ,Emission Tomography ,Lead Principal Investigator ,Executive Chairman ,Targeted Copper Theranostic ,Clin Cancer ,Cancer Statistics ,Mortality Worldwide ,Cancer Society ,Key Statistics ,Prostate Cancer ,Biochemically Recurrent Prostate ,Samanes Gajate ,Recurrent Prostate Cancer ,Diagnostic Performance ,